Physician profile
Nick Florio
NPI 1376998120
$1,638.67
in general payments reported to CMS, 2019-2025
25 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $75.63 · 2024: $547 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $250.75 | 2025 | Zilbrysq, Rystiggo |
| Lilly USA, LLC | $224.12 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Argenx US, INC. | $121.29 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Bayer Healthcare Pharmaceuticals INC. | $101.20 | 2024-2025 | |
| Novo Nordisk INC | $95.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Kyowa Kirin, INC. | $94.56 | 2025 | |
| Glaxosmithkline, LLC. | $82.48 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Calliditas Therapeutics US INC. | $81.35 | 2024-2025 | Tarpeyo |
| Inspire Medical Systems, INC. | $76.00 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $57.95 | 2024-2025 | Wainua, Farxiga |
| Irhythm Technologies, INC. | $54.37 | 2024 | Zio Xt Patch, Zio Monitor |
| Otsuka America Pharmaceutical, INC. | $48.16 | 2024-2025 | Jynarque |
| Corcept Therapeutics | $40.82 | 2024-2025 | Korlym |
| Janssen Biotech, INC. | $34.35 | 2025 | |
| Globus Medical, INC. | $32.94 | 2025 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.86 | 2024 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $31.98 | 2025 | |
| Abbvie INC. | $28.95 | 2025 | |
| Csl Behring | $28.61 | 2025 | Hizentra |
| Insulet Corporation | $25.80 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $23.57 | 2025 | Keveyis |
| Radius Health, INC. | $21.91 | 2025 | Binosto, Tymlos |
| Almatica Pharma LLC | $18.32 | 2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $15.95 | 2024 | Crysvita |
| Catalyst Pharmaceuticals, INC. | $14.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Florio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.